To assess the cost-effectiveness of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for adults with acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG).
No takes yet. Share an insight, caveat, or question.
Siddiqi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: